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Abstract: Clinical and laboratory features
and the outcome of ten cases (nine female,
one male) (age range 7-14 years, mean
10.7±2.2 years) with autoimmune hepatitis
are described. The diagnosis was established
by the laboratory features of elevated serum
transferases,
hypergammaglobulinemia,
presence of autoantibodies, liver histology,
excluding viral and metabolic etiologies and
by a prompt response to corticosteroid
therapy. One patient was associated with
celiac disease. Chronic active hepatitis was
present histologically in seven children while
in three, cirrhosis with portal hypertension
had already been established. All patients
received steroids. Azathioprine was instituted
in three patients in addition to steroid
therapy. The patients were followed up for 19 years (mean 4.1±3.0 years). One patient
relapsed during maintenance therapy, and
two patients died within less than one year

Department of Paediatric, Division of Pediatric
Gastroenterology, Faculty of Medicine, AnkaraTurkey

Introduction
Autoimmune hepatitis (AIH) is an inflammatory liver
disease of unknown etiology characterized by
autoantibodies and histological features of chronic active,
periportal hepatitis (1). Progressive destruction of the
hepatic paranchyma often progresses to cirrhosis and it
carries a high mortality if untreated (2). AIH has two
peaks of incidence, one being between the ages of 10 and
20 (1). Only a few large series of children with AIH have
been reported (2-6). We present clinical and laboratory
features and the outcome of ten children with AIH.
Materials and Methods
Ten patients diagnosed as having AIH in our center are
presented. Of the ten children, nine were girls and one
was a boy, mean age 10.7±2.2 years (range 7-14 years).

probably because of poor compliance to
treatment. In one patient treatment was
withdrawn after three years and no relapse
occurred during the six months of follow-up.
Control liver biopsies were done in six
patients after two years of treatment in
which five showed histological improvement.
We conclude that autoimmune hepatitis in
childhood has a wide spectrum of clinical
features including the absence of symptoms,
acute hepatitis and established cirrhosis with
portal hypertension. Autoimmune hepatitis
should be kept in mind in the differential
diagnosis of both acute and chronic liver
diseases of children. Autoimmune hepatitis
carries a high mortality if left untreated but
has a favourable outcome when treatment is
initiated early in the course of the disease.
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Diagnosis was based on routine biochemical and
immunologic analysis, histopathology of the liver and
exclusion of viral and metabolic etiologies. Drug
consumption or exposure to toxic agents were excluded in
all patients. Hepatitis B virus, hepatitis C virus, EpsteinBarr virus and Cytomegalovirus were excluded by
appropriate serologic markers. Wilson’s disease was
excluded in all by normal serum ceruloplasmin and normal
24-hour urinary copper excretion as well as negative
copper staining and normal hepatic copper concentration
in liver biopsies. Alpha-1 antitrypsin concentrations were
within normal limits in all patients.
Alanine aminotransferase (ALT) was measured by the
hospital laboratory. Antinuclear antigen (ANA), smooth
muscle antibody (SMA) and liver-kidney-microsomal
antibody (LKM-1) were tested at a dilution of 1:10 in
phosphate-buffered
saline
by
indirect
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immunofluorescence.
Serum
immunoglobulin
concentrations were measured by laser nephelometry
(Behringwerke AG, Marburg, Germany).
Liver histology was interpreted using conventional
criteria (7).
Treatment: After the diagnosis, all patients were put
on prednisolone treatment at a dose of 2 mg/kg/day
(maximum 60 mg/day). This dose was gradually tapered
by 5 mg every week after the first week of therapy until
the maintenance dose of 15 mg/day was achieved.
Azathioprine (2 mg/kg/day) was added to steroid therapy
in three patients because the dosage of steroid had to be
reduced due to significant side effects such as glucose
intolerance (in two) and hypertension (in one). In three
patients Azathioprine was used temporarily due to the
development of cataract. No other immunosuppressants
were used.
Results
The symptoms were as follows: jaundice in nine (six of
them acute onset, and three relapsing), epistaxis in two
and anorexia, fatigue and malaise in four. One patient had
no symptoms attributable to liver disease, she was
admitted to hospital for evaluation of short stature and
chronic diarrhea, and celiac disease was diagnosed based
on serology and histological criteria. AIH was diagnosed
in this patient with further evaluation when persisting
enzyme elevation was noticed.
In three out of the ten children, the duration of
symptoms was more than six months while in six, it was
between a week to four months (mean 23.1±22.6
week). One patient had no symptoms attributable to liver
disease. Pathological physical examination findings at
presentation were icterus in eight, hepatomegaly in nine,
splenomegaly in six and ascites in one. Physical findings of
chronic liver disease such as spider nevus and palmar
erythema were found in two patients. In one patient (case
2), the only pathologic finding at examination was short
stature.
Portal system Doppler ultrasound and/or upper
gastrointestinal endoscopy was performed for evaluation
of the presence of portal hypertension which revealed
positive results in six patients.
Demographical characteristics, symptoms and physical
examination findings of the patients are shown in Table I.
All of the children had a 4 to 15 fold elevation of ALT.
IgG levels were above 20 g/L in all patients, in seven of
them it was above 30 g/L. All but one were ANA and/or
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SMA positive (titer range, 1/40-1/160). In eight of these
patients, ANA and/or SMA positivity was found at
presentation while one became ANA positive after two
months of steroid treatment. In the patient without ANA
and/or SMA positivity, the diagnosis was confirmed by
laboratory features of elevated serum transferases,
hypergammaglobulinemia, liver histology and by rapid
response to corticosteroid therapy. We were able to
analyse LKM-1 antibody only in four recently diagnosed
patients in whom the results were negative. Coombs tests
were positive in two, but neither of them had hemolytic
anemia. None had anti-thyroid, anti-insulin or anti-islet
cell antibodies. One patient had an associated disorder,
celiac disease (case 2). Liver histology revealed chronic
active hepatitis with portal tract inflammation,
periportal/periseptal necrosis and lymphocytic aggregate
in three patients. In four patients septal bridging fibrosis
was found in addition to the above histologic findings,
while in three, definite cirrhosis was present. Table II
shows the laboratory and liver histologic features of the
patients.
After the diagnosis, all patients were put on
prednisolone treatment (2 mg/kg/day, max 60 mg/day).
This dose was gradually tapered by 5 mg every week
after the first week of therapy and maintained on 15
mg/day. Three patients received Azathioprine (2
mg/kg/day) in addition to steroid therapy because of
significant side effects (glucose intolerance in two
patients during the second and third months of therapy
and hypertension in one patient during the first week of
therapy). In three patients, cataracts developed during
the second year of therapy which regressed in two
months after switching to Azathioprine and did not recur
after re-administration of steroids. Psychiatric symptoms
such as delirium, depression or attempted suicide were
observed in three of the children during the initial phase
of treatment. In one patient intraocular pressure was
elevated temporarily. The longest duration of treatment
in our group is nine years. Therapy was withdrawn in one
patient after 3 years due to histologic resolution. At the
time of writing she had been off therapy for 6 months
without recurrence. During the period of observation (19 years, mean: 4.1±3.0 years), one patient had an
episode of relapse during maintenance therapy which
responded to an increased dose of prednisolone. One
patient was lost to follow-up after one year, and one
patient was followed up in another hospital. Among the
ten patients, except for one lost to follow-up, seven of
them are alive, six on maintenance therapy and one off
therapy (at the time of writing). Two patients died within
less than one year (8 and 10 months) after the diagnosis
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Table 1.

No

Demographical characteristics, symptoms and physical examination findings of the patients.

Name, Sex,

Symptoms

Age (years)

Duration of

Physical examination findings

symptoms
1 week

Portal
hypertesion

1

(M.Ö), F, 11

jaundice, vomiting

icterus, hepatosplenomegaly

-

2

(B.E), F, 13

no symptoms

H : -3,05
SDS
WSDS: -2.40

3

(F.G), F, 14

jaundice, malaise, fatigue, anorexia

2 weeks

icterus, hepatomegaly

-

4

(F.G), F, 12

jaundice, epistaxis

16 weeks

icterus, hepatomegaly

+

5

(F.K), F, 8

jaundice, malaise, fatigue, anorexia

1 week

icterus, hepatosplenomegaly

-

6

(H.A), F, 9

jaundice, malaise, fatigue

16 weeks

icterus, hepatosplenomegaly, ascites

+

7

(E.A), F, 7

epistaxis, relapsing jaundice

52 weeks

icterus, hepatosplenomegaly

+

8

(B.E), M, 12

relapsing jaundice

52 weeks

hepatomegaly, spider nevus,
palmar erythema, gynecomastia

+

9

(S.H), F, 11

jaundice, malaise, fatigue

16 weeks

icterus, hepatosplenomegaly, spider nevus

+

10

(H.O), F, 10

relapsing jaundice

52 weeks

icterus, hepatosplenomegaly

+

probably due to poor compliance to treatment. Control
liver biopsies were performed in six patients after two
years of treatment in which five showed histological
improvement. In four of these patients, significant
histological improvement was demonstrated (minimal to
mild disease activity), while in one, chronic active hepatitis
with bridging necrosis persisted which had cirrhosis
initially. The patient who relapsed showed no histological
improvement. Treatment, complications, and follow-up
results of the patients are shown in Table III.
Discussion
Autoimmune hepatitis (AIH) is a rather uncommon
progressive inflammatory liver disease characterized
histologically by dense mononuclear cell infiltrates in the
portal tracts and serologically by the presence of
nonorgan and liver specific autoantibodies in the absence
of a known etiology (1). The etiology and the
pathogenesis of AIH remain largely unknown but the loss
of tolerance against autologous liver tissue in a genetically
predisposed host exposed to an environmental agent is
regarded as the principal pathogenetic mechanism (8, 9).
Environmental triggering agents are unknown but some
viruses or drugs such as measles, hepatitis C, Ebstein
Barr, hepatitis A virus or interferon treatment are
thought to trigger AIH (8, 10). Untreated AIH carries an
unfavorable prognosis and many cases progress to
cirrhosis with high mortality, therefore the diagnosis
should be made as soon as possible (2). With treatment

however, the survival rate improves (11).
Earlier descriptions of the disease noted its chronic,
but fluctuating course and it was generally accepted that
for a diagnosis to be made, six months’ duration of
symptoms were required. Patients most often present
with insidious onset of malaise, anorexia and fatigue but
other presentations include advanced cirrhosis with
findings of portal hypertension, apparent acute hepatitis
with jaundice resembling viral hepatitis and a severe
fulminant course (12-14). Completely asymptomatic
cases in which the disease is discovered when abnormal
serum enzyme values are obtained at routine health
screening have also been described (15). Reports suggest
that a 6-month duration of hepatic illness should not be a
prerequisite for the diagnosis of AIH (16, 17). In our
group of AIH patients, only three out of the ten children
had a history of hepatic symptoms of six or more months
of duration while in six of them the duration of symptoms
was between a week and four months. One patient had
no symptoms at all attributable to liver disease. Three of
the patients presented like an acute viral hepatitis, while
in three, advanced cirrhosis with portal hypertension had
already been established at the time of diagnosis.
Conventional diagnostic criteria include three to ten
fold elevations of serum aminotransferase activities,
hypergammaglobulinemia, high titers of circulating ANA,
SMA or LKM-1 and exclusion of all other possible
etiological factors (1, 8, 9). It is agreed that for children,
lower titers of antibodies are sufficient for a diagnosis of
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Table 2.

Laboratory and liver histologic features of the patients.

Patient
no

ALT
(U/L)

IgG
(g/L)

ANA

SMA

LKM

Coombs

Anti-thyroid
antibody

Anti-insulin
antibody

Anti-islet
cell antibody

Histologic features

1
2
3
4
5
6
7
8
9
10

328
171
430
126
481
230
239
139
112
234

48.7
24.6
30.7
25.4
41.8
42.2
51.0
47.2
45.5
25.3

+
+
+
+
+
+
+

+
+
+
+
+
+
-

ND*
ND
ND
ND
ND
ND

+
+
-

-

-

-

CAH** (bridging necrosis)
CAH
CAH (bridging necrosis)
CAH (bridging necrosis)
CAH (bridging necrosis)
CAH
CAH
Cirrhosis
Cirrhosis
Cirrhosis

* ND: Not done
** CAH: Chronic active hepatitis
Table 3.

Treatment, complications and follow-up results of the patients.

Patient no

Treatment

Duration of treatment

Complications of treatment

1

steroid

2 years (still continuing)

cataract

2 year

mild disease activity

Alive

2

steroid

5 years (still continuing)

-

5 years

mild disease activity

Alive

3

steroid

therapy withdrawn)

cataract

3.5 years

minimal disease activity

Alive

steroid+

9 years

glucose intolerance,

4

Duration of follow-up

Control biopsy

Status

3 years (steroid

AZA*

depression, delirium

9 years

CAH** (bridging necrosis)

Alive

5

steroid

3.5 years (still continuing)

cataract

3.5 years

mild disease activity

6

steroid

2 years

depression, attempted suicide

lost to follow-up

ND***

?

7

steroid

1 year

glaucoma

follow-up in another hospital

ND

Alive

8

steroid

8 years

-

8 years

CAH (bridging necrosis)

Alive

ND

Exitus

ND

Exitus

9
AZA*

steroid+
10 months

hypertension, delirium

1 year

8 months

glucose intolerance

1 year

10
AZA*

Alive

steroid+

* AZA: Azathioprine
** CAH: Chronic active hepatitis
*** ND: Not done

AIH (1). In childhood, AIH is associated with either the
presence of ANA/SMA antibody in the serum which is
classified as type 1 AIH or with the LKM-1 antibody in the
serum which is called type 2 AIH (18). In the present
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study, all had 4 to 15 fold elevated levels of ALT, all but
one had ANA/SMA positivity in a titer of 1/40 or more.
Gregorio et al. (2), in their large series of 52 children,
reported ANA/SMA positivity in 32 children. We were not
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able to analyse other antibodies described to be present
in AIH such as antiactin, anti liver pancreas, soluble liver
or liver cytosolic antibodies (19), yet LKM-1was negative
in four children in whom the test could be done. The
diagnosis in the patient without detectable antibodies was
established by the laboratory features of elevated serum
transferases, hypergammaglobulinemia, liver histology,
excluding viral and metabolic etiologies and by a prompt
response to corticosteroid therapy.
AIH has associations with other autoimmune
disorders (1). In the present study, we did not find any
evidence of associated thyroid disease which is stated to
be the most common autoimmune disease found in AIH.
Although hemolytic anemia was not present, Coombs
positivity was determined in two of our patients which
became negative soon after initiation of steroid therapy.
One interesting finding in our group was a case associated
with celiac disease. Reversible liver involvement of a wide
spectrum ranging from asymptomatic transaminase
elevations to chronic active hepatitis or cirrhosis is well
known in active phase of celiac disease (20, 21). On the
other hand, an increased prevalence of autoimmune
diseases among celiac subjects and an increased
prevalence of celiac disease among those affected by
autoimmune diseases have long been known (22). This
prevalence is ascribed to shared genetically predisposing
factors, especially some HLA antigens. Primary biliary
cirrhosis and primary sclerosing cholangitis have been
reported to be associated with celiac disease (23, 24). In
the literature, there are only a few cases describing the
association between celiac disease and AIH (25-27). The
case of AIH associated with celiac disease presented in this
series, had classical symptomatology, physical findings,
laboratory features, and histological findings of gluten
sensitive enteropathy. She had been followed up for six
months with gluten-free diet, but her ALT elevation
persisted. Liver enzyme elevations seen in some celiac
patients are reported to be normalized after gluten-free
diet within one to three months (20). It was her
persisting aminotransferase elevations which necessiated
a work-up for chronic liver diseases during which she was
diagnosed as having AIH with hypergammaglobulinemia,
presence of ANA and SMA antibody, and histological
findings in a liver biopsy. We think that the association of
celiac disease in our relatively small group of AIH deserves
attention.
Previous reports of AIH including both adults and
children indicate that ANA/SMA positive AIH (type 1 AIH)
has a relatively benign course whereas LKM-1 positive
AIH disease (type 2 AIH) is severe and mortality is high
despite appropriate therapy (28). Recently, Maggiore and

Gregorio, separately concluded that the severity and longterm outcome of type 1 or type 2 AIH of childhood is
similar (2, 3). In the present study there was only one
patient who was negative for ANA and SMA and the LKM
status is unknown. So it is impossible to comment on the
outcome of the different two subtypes of AIH in our
study group.
Prednisolone and Azathioprine are the major drugs of
choice either used alone or in combination whether the
histological appearence is that of severe hepatitis, with or
without fibrosis or cirrhosis (8, 29). Although patients
may remain in remission or have only mild disease activity
when the treatment is withdrawn, in the majority of
patients therapy needs to be continued life long. There
are no firm guidelines for the withdrawal of treatment
(8). In our group all the patients received steroids as the
initial therapy; in three of them Azathioprine was added
to reduce the steroid dose because of significant side
effects. In two other patients Azathioprine was used only
temporarily because steroids had to be stopped due to
cataract formation. We attempted to withdraw the drug
only in one patient and she continued to be in remission
for 6 months at the time of writing. Seven out of the ten
children in the present study were alive for the
observation period of 4.1±3.0 years. The two patients
who died a few months after diagnosis, and the one who
relapsed, were the children who received Azathioprine in
combination with steroids and they were actually the
patients with poor treatment compliance. It is impossible
to compare the efficacy of steroids with Azathioprine
therapy in our relatively small group of children with AIH
but we can conclude that AIH in childhood has a favorable
outcome when treatment is initiated early in the course of
the disease.
It has been stated that treatment failures occur in
about 20% of patients with AIH and that it is more
frequent in those with established cirrhosis and in
general, the prognosis is inversely correlated with the
histological severity of the disease. Indeed, the two
patients in our series who died were the patients
presented initially with histologically proven cirrhosis
associated with portal hypertension. The clinical history
of one of them included relapsing jaundice for a year
before therapy was instituted. These observations
confirm the opinion of needing to diagnose and to
institute the treatment as soon as possible (8). Based on
our observations, we also conclude that fibrosis of the
liver may be resolved in AIH following protracted and
effective treatment. In all of our patients with good
compliance to treatment, significant histologic
improvement was demonstrated within two years of
therapy.
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In summary, AIH in childhood has a wide spectrum of
clinical features that extends from the absence of
symptoms to an acute, even fulminant hepatitis. Although
considered rare, AIH should be kept in mind in the
differential diagnosis of both acute and chronic liver
diseases of children after excluding the relatively more
commonly seen viral and metabolic diseases. AIH

progresses to cirrhosis when left untreated, but early
diagnosis and treatment prolong survival.
Correspondence author:
Ayhan KANSU
Yılmaz Çolpan Sok. 46/1
OR-AN Sitesi 06450 Ankara-TURKEY
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